Congress Data Presentations | ADC Therapeutics

Clear Filters

Type

Product/compound

Congress

Year

All
Poster
Oral Presentation

All
Loncastuximab Tesirine
Other Compounds

All
AACR
ACCP
ACoP
AMCP Nexus
ASCO
ASH
CTOS
EHA
EORTC-NCI-AACR
ESMO
HOPA
ICML
ISPOR
NCCN
ONS
PPLC
SITC
SOHO
Tandem

All
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Oral Presentation

ASH 2025

Deep responses following treatment with loncastuximab tesirine in patients with relapsed/refractory including those with high-risk, TP53-altered Waldenström macroglobulinemia

Independent Investigator-Initiated

Poster

ASH 2025

Consolidation with Loncastuximab Tesirine for Large B-cell Lymphoma Patients in Partial Response After CART: Planned Interim Futility Analysis of a Phase II Trial

Independent Investigator-Initiated

Poster

ASH 2025

Efficacy and Safety of Loncastuximab tesirine and Rituximab (Lonca-R) Followed by DA-R-EPOCH in Previously Untreated High-Risk DLBCL: Preliminary Results from UCDCC#303, a UCHMC Phase II Trial

Independent Investigator-Initiated

Oral Presentation

ICML 2025

Initial Results From LOTIS-7: A Phase 1b Study of Loncastuximab Tesirine Plus Glofitamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Poster

EHA 2025

Initial Results From LOTIS-7: A Phase 1b Study of Loncastuximab Tesirine Plus Glofitamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Poster

EHA 2025

Updated Safety Run-In Results From LOTIS-5: A Phase 3, Randomized Trial of Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Patients With R/R DLBCL/HGBL

Oral Presentation

AACR 2025

Preclinical investigation of ADCT-242, a novel exatecan-based antibody drug conjugate targeting Claudin-6, as single agent or in combination in ovarian and non-small lung cancer models

Poster

AACR 2025

Preclinical development of ADCT-241, a novel exatecan-based antibody-drug conjugate targeting PSMA for the treatment of prostate cancer

Poster

AACR 2025

HuB14-VA-PL2202, a novel antibody-drug conjugate targeting ASCT2, a novel ADC target over-expressed in both solid and hematological cancers

Poster

ASH 2024

A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Independent Investigator-Initiated

Poster

ASH 2024

Limited Duration Loncastuximab Tesirine Induces a High Rate of Complete Responses in Patients with Relapsed/Refractory Marginal Zone Lymphoma – Report of First Planned Interim Futility Analysis of a Multicenter Phase II Study

Independent Investigator-Initiated

Poster

ASH 2024

Loncastuximab Tesirine in Combination with Venetoclax Is Safe and Shows Efficacy in Patients with Relapsed/Refractory Non Hodgkin Lymphoma

Independent Investigator-Initiated

Poster

ASH 2024

A phase II trial of loncastuximab tesirine in patients with previously treated Waldenström macroglobulinemia

Independent Investigator-Initiated

Oral Presentation

ASH 2024

Loncastuximab Tesirine with Rituximab Induces Robust and Durable Complete Metabolic Responses in High-Risk Relapsed/Refractory Follicular Lymphoma

Independent Investigator-Initiated

Poster

CTOS 2024

Quantitative Systems Pharmacology Modeling of Mipasetamab Uzopterine Integrates Knowledge and Defines Dosing Strategy for Patients With Sarcoma

Poster

ACoP 2024

Quantitative Systems Pharmacology Modeling of Loncastuximab Tesirine Combined With Mosunetuzumab and Glofitamab Helps Guide Dosing for Patients With DLBCL

Poster

EORTC-NCI-AACR 2024

Preclinical characterization of NaPi2b-PL2202, a novel exatecan-based antibody drug conjugate

Poster

PPLC 2024

Phase 1b Open-Label Study Of Loncastuximab Tesirine In Combination With Other Anticancer Agents In Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (LOTIS-7)

Poster

PPLC 2024

Quantitative Systems Pharmacology Model Predicts Combination Activity of CD19-Targeted Loncastuximab Tesirine Codosed With a CD20/CD3 T-cell Bispecific (Epcoritamab) in Diffuse Large B-cell Lymphoma

Poster

ASCO 2024

LOTIS-5, an Ongoing, Phase 3, Randomized Study of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCL

Poster

AACR 2024

Quantitative systems pharmacology modeling of loncastuximab tesirine combined with mosunetuzumab and glofitamab helps guide dosing for patients with DLBCL

Poster

AACR 2024

Preclinical anti-tumorigenic evaluation of AXL antibody-drug-conjugate in an adenoid cystic carcinoma cell line xenograft model

Independent

Poster

AACR 2024

Phase 1b Trial Mipasetamab Uzoptirine (ADCT-601-102) dose escalation in patients with advanced bone and soft tissue sarcomas

Poster

AACR 2024

Preclinical development of a novel camptothecin-based antibody-drug conjugate targeting solid tumors expressing Claudin-6

Poster

AACR 2024

Preclinical development of NaPi2b-PL2202, a novel camptothecin-based antibody-drug conjugate targeting solid tumors expressing NaPi2b

Poster

Tandem 2024

Limited duration loncastuximab with rituximab induces high complete response rate in high-risk relapsed/refractory follicular lymphoma – A phase 2 study

Independent Investigator-Initiated

Poster

Tandem 2024

Real-World Clinical Effectiveness of Loncastuximab Tesirine Monotherapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Following Chimeric Antigen T Cell Therapy in the US

Poster

ASH 2023

A Phase II Study of Loncastuximab Tesirine As Consolidation Strategy in Patients with LBCL in PR at Day 30 after CAR T-Cell Therapy

Poster

ASH 2023

Hematopoietic Stem Cells Expressing Engineered CD45 Enable a Near Universal Targeted Therapy for Hematologic Diseases

Poster

ASH 2023

A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma (Glo-BNHL)

Poster

ASH 2023

Early and Sustained Circulating Tumor DNA Response Dynamics after Loncastuximab Tesirine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Poster

ASH 2023

Loncastuximab Tesirine Demonstrated Substantial Single-agent Efficacy and Manageable Safety Profile in Heavily Pretreated Chinese Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Oral Presentation

ASH 2023

Limited duration loncastuximab with rituximab induces high complete response rate in high-risk relapsed/refractory follicular lymphoma – A phase 2 study

Independent Investigator-Initiated

Poster

ACCP 2023

A Clinical Quantitative Systems Pharmacolgy Framework Describing Loncastuximab Tesirine Distribution and the Exploration of Patient Outcomes From the LOTIS-2 Clinical Trial in Patients with B-cell Lymphomas

Poster

SOHO 2023

Phase 1b open-label study of loncastuximab tesirine in combination with other anticancer agents in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (LOTIS-7)

Independent Investigator-Initiated

Poster

SOHO 2023

Updated Results of the Safety Run-In of the Phase 3 LOTIS-5 Trial: Novel Combination of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCL

Oral Presentation

ICML 2023

Long-Term Responses With Loncastuximab Tesirine: Updated Results From LOTIS-2, the Pivotal Phase 2 Study of Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Oral Presentation

ICML 2023

Long-Term Responses With Loncastuximab Tesirine: Updated Results From LOTIS-2, the Pivotal Phase 2 Study of Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Poster

EHA 2023

Long-Term Responses With Loncastuximab Tesirine: Updated Results From LOTIS-2, the Pivotal Phase 2 Study of Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Poster

ASCO 2023

Phase 1b open-label study of loncastuximab tesirine in combination with other anticancer agents in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (LOTIS-7)

Poster

AACR 2023

Discovery of plasma protein biomarkers associated with overall survival in R/R DLBCL patients treated with loncastuximab tesirine

Poster

AACR 2023

Preclinical development of ADCT-212, a PSMA-targeted antibody-drug conjugate employing the pyrrolobenzodiazepine dimer SG2000 for PSMA-expressing cancers

Poster

AACR 2023

Preclinical development of ADCT-211, a novel pyrrolobenzodiazepine dimer-based antibody-drug conjugate targeting solid tumors expressing IL13RA2

Poster

AACR 2023

A Phase 1/2 Randomized Study of Imvotamab Monotherapy and in Combination with Loncastuximab Tesirine in Relapsed/Refractory Non-Hodgkin Lymphomas

Oral Presentation

ASH 2022

ADCT-602, a CD22 Targeting Antibody Drug Conjugate Bound to PBD Toxin in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia A Phase 1 Trial

Independent

Oral Presentation

ASH 2022

Real‐World Effectiveness and Economic Impact Associated with Chimeric Antigen Receptor T‐cell Therapy Among Older Patients with Relapsed/Refractory Diffuse Large B‐Cell Lymphoma in US

Poster

ASH 2022

CD25, Soluble CD25, and CCL17 as Potential Predictors of Clinical Response to Camidanlumab Tesirine in Patients With R/R Classical HL

Poster

ASH 2022

CD19 Expression by IHC Alone Is Not a Predictor of Response to Loncastuximab Tesirine: Results From LOTIS-2 and Quantitative Systems Pharmacology Modeling

Poster

ASH 2022

Development of Anti-CD45 Antibody Drug Conjugates As Targeted Conditioning Agents for Transplantation/Gene Therapy with Potent Anti-Leukemic Properties. “is not available at this time”

Poster

ASH 2022

Real-world Outcomes in Relapse/Refractory DLBCL Patients Who Received Polatuzumab Vedotin Plus Bendamustine and Rituximab or Tafasitamab Plus Lenalidomide by Line of Therapy

Poster

ASH 2022

A Phase 2, Open-Label Study of Loncastuximab Tesirine in Combination With Rituximab in Previously Untreated Unfit/Frail Patients With DLBCL (LOTIS-9)

Poster

ASH 2022

Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data From the Open-Label, Multicenter, Phase 2 Study of Patients With R/R cHL

Poster

ASH 2022

Identification of predictive biomarkers for response of R/R DLBCL patients treated with loncastuximab tesirine using low-pass whole-genome cell-free DNA sequencing (cfDNA-WGS)

Poster

SOHO 2022

A Phase 2, Open-Label Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9)

Poster

SOHO 2022

Health-Related Quality of Life and Tolerability in Patients With/Without Skin Toxicity During Loncastuximab Tesirine Treatment in a Phase 2 Clinical Trial (LOTIS-2)

Poster

SOHO 2022

Initial Safety Run-In Results of the Phase 3 LOTIS-5 Trial: Novel Combination of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCL

Poster

SOHO 2022

Long-Term Survival Projections of Loncastuximab Tesirine‒Treated Patients in Relapsed or Refractory Diffuse Large B-cell Lymphoma

Poster

SOHO 2022

Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

Oral Presentation

SOHO 2022

Camidanlumab tesirine: updated efficacy and safety in an open-label, multicenter, phase 2 study of patients with relapsed or refractory classical Hodgkin lymphoma (R/R cHL)

Oral Presentation

EHA 2022

Camidanlumab tesirine: updated efficacy and safety in an open-label, multicenter, phase 2 study of patients with relapsed or refractory classical Hodgkin lymphoma (R/R cHL)

Poster

EHA 2022

Health-Related Quality of Life and Tolerability of Loncastuximab Tesirine in High-Risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated in a Phase 2 Clinical Trial (LOTIS-2)

Poster

EHA 2022

Real-World characteristics and clinical outcomes in relapse/refractory diffuse large B-Cell lymphoma patients who received CAR-T therapy

Poster

EHA 2022

Real-World characteristics and clinical outcomes in relapse/refractory diffuse large B-Cell lymphoma post CAR-T failure

Poster

ASCO 2022

First-in-Human, Phase 1, Open-Label, Dose-Escalation Study of ADCT-901 as Monotherapy in Patients With Select Advanced Solid Tumors

Poster

ASCO 2022

Phase 3 Randomized Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCL LOTIS-5

Poster

ONS 2022

Onset, Duration, and Management of Edema and Effusion in Patients Treated With Loncastuximab Tesirine for R/R DLBCL: Updated Results From the LOTIS-2 Clinical Trial

Poster

ONS 2022

Characterization and Management of Cutaneous Reactions in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With Loncastuximab Tesirine in the LOTIS-2 Trial

Poster

AACR 2022

Effect of Camidanlumab Tesirine (Cami) as Monotherapy and in Combination With Pembrolizumab (PEM) on the Immune Cell Profile in Patients With Selected Advanced Solid Tumors

Poster

AACR 2022

Mechanistic studies investigating the synergistic combination of Loncastuximab Tesirine and Ibrutinib in pre-clinical models of B-Cell non-Hodgkin lymphoma

Poster

AACR 2022

AXL as a therapeutic target in adenoid cystic carcinoma: preclinical evaluation of AXL targeting antibody-drug conjugate (ADCT-601)

Poster

NCCN 2022

Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Older Versus Younger Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated in a Phase 2 Clinical Trial (LOTIS-2)

Poster

HOPA 2022

A Pooled Safety Analysis of Loncastuximab Tesirine in R/R DLBCL in the LOTIS Clinical Trial Program: Incidence, Onset, and Management of Myelosuppression

Poster

ASH 2021

Clinical Characteristics and Responses of Patients with Relapsed or Refractory High‐Grade B‐Cell Lymphoma Treated with Loncastuximab Tesirine in the LOTIS‐2 Clinical Trial

Poster

ASH 2021

Combination of Loncastuximab Tesirine and Polatuzumab Vedotin Shows Increased Anti-Tumor Activity in Pre-Clinical Models of Non-Hodgkin Lymphoma

Poster

ASH 2021

CD19-mediated DNA Damage Boost in Lymphoma Cells Treated with Loncastuximab Tesirine in Combination with PARP Inhibitors

Oral Presentation

ASH 2021

Planned Interim Analysis of a Phase 2 Study of Loncastuximab Tesirine Plus Ibrutinib in Patients with Advanced Diffuse Large B‐Cell Lymphoma (LOTIS‐3)

Poster

ASH 2021

A Phase 1 Trial of ADCT-602, a CD22 Targeting Antibody Drug Conjugate Bound to PBD Toxin in Adult Patients with Relapsed or Refractory CD22+ B-Cell Acute Lymphoblastic Leukemia

Independent

Poster

ASH 2021

Clinical Characteristics and Responses of Patients With Relapsed or Refractory High-Grade B-Cell Lymphoma Treated With Loncastuximab Tesirine in the LOTIS-2 Clinical Trial

Poster

ASH 2021

The Anti-CD19 Antibody-Drug Conjugate Loncastuximab Tesirine Achieved Responses in Patients With Diffuse Large B-Cell Lymphoma Who Relapsed After Anti-CD19 CAR T-Cell Therapy

Independent

Poster

ASH 2021

Phase 1 Trial of ADCT-602, a CD22 Targeting ADC Bound to PBD Toxin in Adult Patients With RR CD22+ B-Cell ALL

Poster

AMCP Nexus 2021

Budget Impact Model for Loncastuximab Tesirine-lpyl in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma

Poster

SOHO 2021

Incidence, onset, and management of myelosuppression in patients treated with loncastuximab tesirine for R/R DLBCL in a pooled safety analysis

Oral Presentation

SOHO 2021

LOTIS-2 follow-up analysis: Updated results from a Phase 2 study of loncastuximab tesirine in relapsed or refractory diffuse large B-Cell lymphoma

Poster

SOHO 2021

Incidence, onset, and management of edema and effusion in patients treated with loncastuximab tesirine for R/R DLBCL in the LOTIS clinical trial program

Poster

ICML 2021

Clinical activity of loncastuximab tesirine plus ibrutinib in non-Hodgkin lymphoma: Updated LOTIS-3 Phase 1 results

Oral Presentation

ICML 2021

Camidanlumab tesirine efficacy and safety in an open-label, multicenter, Phase 2 study of patients with relapsed or refractory classical Hodgkin lymphoma (R/R cHL)

Poster

ICML 2021

LOTIS-2 follow-up analysis: Updated results from a Phase 2 study of loncastuximab tesirine in relapsed or refractory diffuse large B-Cell lymphoma

Poster

ICML 2021

A Phase 3 randomized study of loncastuximab tesirine plus rituximab vs immunochemotherapy in patients with relapsed/refractory diffuse large B-Cell lymphoma — LOTIS-5

Poster

ICML 2021

A Phase 2 randomized study of loncastuximab tesirine (Lonca) vs idelalisib in patients with relapsed or refractory (R/R) follicular lymphoma (FL) — LOTIS-6

Poster

EHA 2021

Duration of Response to Loncastuximab Tesirine in Relapsed/Refractory Diffuse Large B-cell Lymphoma by Demographic and Clinical Characteristics: Subgroup Analyses from LOTIS-2

Poster

EHA 2021

Characteristics and Outcomes in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Who Received ≥3 Lines of Therapies

Poster

ASCO 2021

A Phase 1b, Open-Label, Dose-Escalation Study to Evaluate Camidanlumab Tesirine (Cami) as Monotherapy in Patients with Advanced Solid Tumors

Poster

ASCO 2021

Duration of Response to Lonca RR DLBCL by Demographic Subgroup Analysis from LOTIS

Poster

ASCO 2021

Phase 3 Randomized Study of Lonca plus Rituximab versus Immunochemotherapy in Patients with RR DLBCL LOTIS

Poster

ISPOR 2021

Treatment-Related Costs of Pharmacologic Regimens for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Who Have Received Two or More Prior Lines of Therapies

Poster

AACR 2021

Relationship Between Exposure and Safety/Efficacy of Loncastuximab Tesirine in B-cell Non-Hodgkin Lymphoma

Poster

AACR 2021

Integrated Population Modeling of Loncastuximab Tesirine (Lonca) Exposure in B-cell Non-Hodgkin Lymphoma (B-NHL)

Poster

ASH 2020

Characteristics and Treatment Patterns of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Who Received ≥3 Lines of Therapies in Post CAR-T Era

Poster

ASH 2020

Interim Results of Loncastuximab Tesirine Combined With Ibrutinib in Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma (LOTIS-3)

Poster

ASH 2020

Pharmacokinetic and Pharmacodynamic Correlates From the Phase 1 Study of Camidanlumab Tesirine (Cami) in Patients With Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma

Poster

ASH 2020

Combination of Camidanlumab Tesirine, a CD25-Targeted ADC, with Gemcitabine Elicits Synergistic Anti-Tumor Activity in Preclinical Tumor Models

Poster

ASH 2020

Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients With Relapsed or Refractory Hodgkin Lymphoma

Poster

ASH 2020

Analysis of ADCT-602 Pre-Clinical Activity in B-Cell Lymphoma Models and Identification of Potential Biomarkers for Its Activity

Poster

ASH 2020

Safety and Antitumor Activity Study Evaluating Loncastuximab Tesirine and Rituximab Versus Immunochemotherapy in Diffuse Large B-Cell Lymphoma

Poster

ASH 2020

Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Poster

SITC 2020

A Tregs-depleting CD25-targeted antibody-drug conjugate synergizes with tumor-targeted radiotherapy and systemic interleukin-2 in pre-clinical models of solid cancers

Poster

ESMO 2020

First-in-Human Study of Camidanlumab Tesirine (ADCT-301, Cami), an anti-CD25 Targeted Therapy in Patients (Pts) with Advanced Solid Tumors: Pharmacokinetics (PK) and Biomarker Evaluation

Poster

EHA 2020

Interim results of a phase 1/2 study of loncastuximab tesirine (Lonca) combined with ibrutinib in advanced diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL)

Oral Presentation

EHA 2020

Initial Results of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Poster

ASH 2019

Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Poster

SITC 2019

Pre-clinical characterization of the mechanism of action of a CD25-targeted pyrrolobenzodiazepine dimer-based antibody-drug conjugate targeting regulatory T cells in solid cancers

Poster

ESMO 2019

A Phase 1, Open-label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-601 in Patients with Advanced Solid Tumors

Poster

ICML 2019

The anti-CD25 antibody-drug conjugate camidanlumab tesirine (ADCT-301) presents a strong preclinical activity both as single agent and in combination in lymphoma cell lines

Oral Presentation

ICML 2019

Analysis of Clinical Determinants Driving Safety and Efficacy of Camidanlumab Tesirine (ADCT-301, Cami) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL)

Oral Presentation

ICML 2019

The Antibody-Drug Conjugate (ADC) Loncastuximab Tesirine (ADCT 402) Targeting CD19 Shows Strong in vitro Anti-Lymphoma Activity Both As Single Agents and in Combination

Oral Presentation

ICML 2019

Analysis of Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) by Demographic and Clinical Characteristics in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Poster

AACR 2019

Pre-clinical characterization of 3A4-PL1601, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) directed against KAAG1-expressing malignancies

Poster

ASH 2018

Phase 1 Study of ADCT-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma

Poster

SITC 2018

A CD25-targeted pyrrolobenzodiazepine dimer-based antibody-drug conjugate shows potent anti-tumor activity in pre-clinical models of solid tumors either alone or in combination with a PD-1 inhibitor

Poster

AACR 2018

ADCT-701, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting DLK1-expressing tumors

Poster

AACR 2018

Pre-clinical activity of ADCT-601, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting AXL-expressing tumors

Poster

ASH 2017

Results from an Ongoing Phase 1 Study Indicate ADCT-301 (Camidanlumab Tesirine) Is Well Tolerated in Patients with Relapsed or Refractory CD25-Positive Acute Leukemia

Poster

ASH 2017

Elucidating Exposure-Response (Safety and Efficacy) of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Containing Antibody Drug Conjugate, for Recommended Phase 2 Dose Determination in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Poster

AACR 2017

Characterization of the mechanism of action, pharmacodynamics and preclinical safety of ADCT-402, no. 51 a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting CD19-expressing hematological malignancies

Poster

ASH 2016

ADCT-602 (hLL2-cys-PBD), a new site-specifically conjugated, pyrrolobenzodiazepine (PBD) dimer-based antibody drug conjugate (ADC) targeting CD22-expressing B-cell malignancies

Poster

ASCO 2016

A phase 1 dose-escalation study to evaluate the tolerability, safety, pharmacokinetics, and antitumor activity of ADCT-402 in patients with relapsed or refractory B-Cell lineage non-Hodgkin lymphoma (B-NHL)

Poster

AACR 2015

Pre-clinical Activity of hLL2-PBD, a Novel Anti-CD22 Antibody-Pyrrolobenzodiazepine (PBD) Conjugate in Models of Non-Hodgkin Lymphoma

Congress Presentations

Oral Presentation

ASH 2025

Poster

ASH 2025

Poster

ASH 2025

Oral Presentation

ICML 2025

Poster

EHA 2025

Poster

EHA 2025

Oral Presentation

AACR 2025

Poster

AACR 2025

Poster

AACR 2025

Poster

ASH 2024

Poster

ASH 2024

Poster

ASH 2024

Poster

ASH 2024

Oral Presentation

ASH 2024

Poster

CTOS 2024

Poster

ACoP 2024

Poster

EORTC-NCI-AACR 2024

Poster

PPLC 2024

Poster

PPLC 2024

Poster

ASCO 2024

Poster

AACR 2024

Poster

AACR 2024

Poster

AACR 2024

Poster

AACR 2024

Poster

AACR 2024

Poster

Tandem 2024

Poster

Tandem 2024

Poster

ASH 2023

Poster

ASH 2023

Poster

ASH 2023

Poster

ASH 2023

Poster

ASH 2023

Oral Presentation

ASH 2023

Poster

ACCP 2023

Poster

SOHO 2023

Poster

SOHO 2023

Oral Presentation

ICML 2023

Oral Presentation

ICML 2023

Poster

EHA 2023

Poster